Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

929
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
929
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

936
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
936
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

339
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
339

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Comment on Sakaki et al. Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes.

Diabetes·2026
Same author

Monogenic diabetes in Japan and India: A call for broader screening.

Diabetes research and clinical practice·2026
Same author

Activating Transcription Factor 6α Governs Stress-Adaptive Pancreatic β-Cell Mass Expansion by Coordinating Proliferation and Survival.

Diabetes·2026
Same author

[<sup>18</sup>F]FB(ePEG12)12-Exendin-4 positron emission tomography/magnetic resonance imaging for precise preoperative localization of a pancreatic-head insulinoma: a case report with review of literature.

Endocrine journal·2026
Same author

Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes.

Diabetes·2026
Same author

Seasonal variation in fresh fruit consumption: insights from the Sukoyaka health survey 2019-2020 in Japan.

BMC nutrition·2026

Related Experiment Video

Updated: Mar 28, 2026

Sustained Administration of &#946;-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.8K

[Once-weekly DPP-4 inhibitor].

Norio Harada, Nobuya Inagaki

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |December 16, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Trelagliptin, a once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, effectively lowers blood glucose in Japanese patients with type 2 diabetes. It demonstrates sustained efficacy and a favorable safety profile, without impacting body weight or hypoglycemia frequency.

    More Related Videos

    Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    9.8K
    Improving IV Insulin Administration in a Community Hospital
    12:08

    Improving IV Insulin Administration in a Community Hospital

    Published on: June 11, 2012

    19.5K

    Related Experiment Videos

    Last Updated: Mar 28, 2026

    Sustained Administration of &#946;-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
    09:31

    Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

    Published on: November 5, 2016

    7.8K
    Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    9.8K
    Improving IV Insulin Administration in a Community Hospital
    12:08

    Improving IV Insulin Administration in a Community Hospital

    Published on: June 11, 2012

    19.5K

    Area of Science:

    • Endocrinology
    • Pharmacology
    • Metabolic Diseases

    Background:

    • Dipeptidyl peptidase-4 (DPP-4) inhibitors are crucial for type 2 diabetes management.
    • Current DPP-4 inhibitors often require daily dosing.
    • Novel formulations for improved patient adherence are needed.

    Purpose of the Study:

    • To evaluate the efficacy and safety of trelagliptin, a novel once-weekly DPP-4 inhibitor.
    • To assess the impact of trelagliptin on glycemic control in Japanese patients with type 2 diabetes.

    Main Methods:

    • In vitro studies assessing DPP-4 inhibition.
    • Clinical studies involving 24-week and 52-week monotherapy and add-on therapy with trelagliptin.
    • Evaluation of HbA1c, fasting plasma glucose, body weight, and hypoglycemia frequency.

    Main Results:

    • Trelagliptin demonstrated potent DPP-4 inhibition in vitro.
    • Significant improvements in HbA1c and fasting plasma glucose were observed after 24 and 52 weeks.
    • No significant changes in body weight or increased frequency of hypoglycemic events were noted.

    Conclusions:

    • Trelagliptin offers a highly effective and safe therapeutic option for glycemic control in Japanese patients with type 2 diabetes.
    • The once-weekly dosing regimen enhances convenience and adherence.
    • Sustained efficacy and safety profile support trelagliptin's role in diabetes management.